Bod Australia Limited reported it has made significant progress towards a Phase I clinical trial of its novel pharmaceutical-grade medicinal cannabis extract and delivery system. Bod has engaged with highly credible counter parties to source and develop its clinical trial program as: Cannabis extract ­ globally unique, phytocomplex cannabis extract, sourced from Swiss company Linnea owned by Schwabe and Ipsen - Delivery method ­ exclusively sourced from innovative late-stage specialty pharmaceutical company iX Biopharma Ltd. - Clinical trial program ­ formulation, design and dosage determined by ex-head of global clinical trials of Sirtex Medical Ltd. Bod Australia has now completed an extensive literature review, and has also determined the unique formulation and dosage requirement to be used in the Phase I trial. As a result of the literature review, the company has identified opportunities to improve its trials' clinical design. This improved study design will reduce the cost of conducting the Phase I trial by reducing sample size, without compromising results. It will also significantly shorten the length of the trial to 3 months, rather than the 10-month timeframe originally estimated. Other improvements to the study include access to more data for future studies and formulations, including a comparison to the only other approved medicinal cannabis product that is currently being trialled in the Australian market. The Phase I trial will take place in the first half of 2018 and will assess the safety, tolerability and pharmacokinetics of Bod's unique sublingual formulation of cannabis, utilising Linnea's phytocomplex extract in oil and powder form and iX Biopharma's patented wafer delivery system. Upon the successful completion of the Phase I trial, Bod will investigate opportunities for its Phase II study, with initial target indications focussing on post chemotherapy-induced nausea and vomiting, epilepsy and multiple sclerosis. The intention of the Phase II trial is to provide research into the efficacy of the therapeutic effects of the company's proposed cannabis based product, with the ultimate aim, subject to any regulatory requirements, of becoming the third product in the company's evidenced based natural medicines portfolio alongside Flexofytol and Pinpoint.